80-OR: 670G Clinical Experience
Objective: In September 2016, the FDA approved the Medtronic 670G “hybrid” closed-loop system. In “Auto Mode,” this system automatically controls basal insulin delivery based on CGM data, but requires users to enter carbohydrate intake and blood sugar for boluses. Studies show improved time in range...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective: In September 2016, the FDA approved the Medtronic 670G “hybrid” closed-loop system. In “Auto Mode,” this system automatically controls basal insulin delivery based on CGM data, but requires users to enter carbohydrate intake and blood sugar for boluses. Studies show improved time in range associated with the use of Auto Mode. In an effort to track our real-world experience with this first commercial closed-loop device, we followed pediatric and adult patients placed on the 670G.
Methods: This was a 1-year prospective observational study, recruiting 5/2017-9/2018, of patients with type 1 diabetes, ≥7 years, starting the 670G system.
Results: 84 patients started on the 670G (range 9-61 years), 26 (31%) were |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/db19-80-OR |